Illumina Stock Analysis (NASDAQ:ILMN)

Add to My Stocks
$162.57 $0.27 (0.17%) ILMN stock closing price Jan 13, 2017 (Closing)
Watch Robo Advisor Video of ILMN Stock Analysis
Illumina
Updated on : Jan 13, 2017
previous close
ILMN 162.6 (0%)
S&P 500 2274.6 (0%)
Closing Price On: Jan 13, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
24.8%
Sector Average:
-1.3%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
1.22B
Debt/Equity Ratio:
 0.53
Compared to the industry
Cash Flow
Operating cash flow:
$150.3M
Net Income:
$128.7M
PROS      CONS
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
High Debt Burden
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
ILMN PS :
10.1
Industry PS :
4.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
22.7%
Return on Equity:
21.5%
Free Cash Flow Margin:
15.3%
Double Tap To Exit Full Screen
0:00
/

Illumina Analysis Video

401 6 2

View Illumina stock analysis video. This is our ILMN analyst opinion covering the buy and sell arguments for ILMN stock.

Illumina, Inc. Stock Rating (3.6/5)

Our Illumina stock opinion is based on fundamentals of the company. This Illumina stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ILMN stock?

  • The TTM operating margin was good at 24.8% for Illumina.
  • Net margins stood at a healthy 18.7% (average) for Illumina in the Trailing Twelve Months.
  • Illumina has an attractive ROIC (Return on Invested Capital) of 22.7%
  • Illumina has a good Return On Equity (ROE) of 21.5%.
  • The company has a good Free Cash Flow (FCF) margin of 15.3%.

Should you sell ILMN stock?

  • With a debt/equity ratio of  0.53, Illumina is highly leveraged in comparison to Medical peers.
  • ILMN stock is trading at a PE ratio of 48.5, which is worse than the industry average multiple of 22.1.
  • ILMN stock is trading at a PS multiple of 10.1, which is a negative when compared to the Medical-Biomed-Genetics industry average multiple of 4.5.

Comments on this video and Illumina stock